Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;17(8):432.
doi: 10.1038/s41585-020-0360-6.

Targeting DNA repair defects in prostate cancer

Clemens Thoma  1
Affiliations
Comment

Targeting DNA repair defects in prostate cancer

Clemens Thoma. Nat Rev Urol. 2020 Aug.
No abstract available

PubMed Disclaimer

Comment on

  • Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. de Bono J, et al. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28. N Engl J Med. 2020. PMID: 32343890 Clinical Trial.

References

Original article
    1. de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091–2102 (2020) - DOI
Related articles
    1. Ku, S.-Y. et al. Towards precision oncology in advanced prostate cancer. Nat. Rev. Urol. 16, 645–654 (2019) - DOI
    1. Antonarakis, E. S. Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one? Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-020-0395-x (2020) - DOI - PubMed

LinkOut - more resources